{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:41:46Z","timestamp":1793234506461,"version":"4.5.0"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Modern radiotherapy techniques have improved the safety of prostate cancer treatment, but acute gastrointestinal and genitourinary toxicity remains a common clinical problem. Early identification of patients who are likely to develop treatment-related adverse effects may help optimize supportive care. This study evaluated the relationships between clinical characteristics, radiotherapy planning parameters, systemic inflammatory biomarkers, and acute pelvic toxicity during hypofractionated radiotherapy. Materials and Methods: We retrospectively analyzed 142 patients with histologically confirmed prostate cancer who underwent external beam radiotherapy at the Provincial Integrated Hospital in P\u0142ock, Poland, between October 2024 and March 2026. Clinical, laboratory, and radiotherapy planning data were obtained from institutional electronic records. Laboratory analyses included CRP, creatinine, total leukocyte, neutrophil, lymphocyte, erythrocyte and platelet counts, hemoglobin, and hematocrit. Rectal and bladder toxicity was prospectively graded according to the RTOG\/EORTC criteria at 2 and 4 weeks after treatment initiation. Correlation and multivariable regression analyses were performed to identify factors associated with acute treatment-related toxicity. Results: Radiotherapy significantly reduced leukocyte and lymphocyte counts (both p &lt; 0.001) and produced smaller reductions in erythrocyte count, hemoglobin, hematocrit, and absolute neutrophil count (all p &lt; 0.05). Patients who reported rectal or urinary symptoms early during treatment generally continued to experience toxicity later in the treatment course. Rectal and bladder toxicities were positively correlated, indicating that patients with toxicity affecting one pelvic organ frequently developed symptoms in the other. Routine inflammatory biomarkers and most dosimetric parameters showed limited independent value for predicting clinically relevant acute toxicity. Conclusions: Early gastrointestinal and genitourinary toxicity appears to be a useful clinical indicator of persistent treatment-related symptoms during hypofractionated prostate radiotherapy. Early rectal and bladder toxicity was associated with toxicity later during treatment, whereas routine laboratory markers and most dosimetric parameters showed limited independent associations with acute pelvic toxicity.<\/jats:p>","DOI":"10.3390\/curroncol33080479","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:08:29Z","timestamp":1786694909000},"page":"479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Routine Inflammatory and Hematological Markers and Acute Radiation Toxicity in Patients with Prostate Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Jolanta","family":"\u0141uniewska-Bury","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum, The Mazovian University in P\u0142ock, 2 Pl. D\u0105browskiego Street, 09-402 P\u0142ock, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Le\u015bniak","sequence":"additional","affiliation":[{"name":"Provincial Integrated Hospital in P\u0142ock, 19 Medyczna Street, 09-400 P\u0142ock, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Majchrzak","sequence":"additional","affiliation":[{"name":"Department of General, Functional and Oncological Urology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-3606","authenticated-orcid":false,"given":"Kamil","family":"Obel","sequence":"additional","affiliation":[{"name":"Warsaw Bar Association, 15\/16 \u017bytnia Street, 01-014 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-4171","authenticated-orcid":false,"given":"Tomasz W.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Hemostasis and Thrombosis Program, Versiti Blood Research Institute, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Z\u0105bkowski","sequence":"additional","affiliation":[{"name":"Department of General, Functional and Oncological Urology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Syry\u0142o","sequence":"additional","affiliation":[{"name":"Department of General, Functional and Oncological Urology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ching, J.C.F., Liu, K.C.K., Pang, I.K.H., Nicol, A.J., Leung, V.W.S., Cai, J., and Lee, S.W.Y. (2025). Predictive factors for gastrointestinal and genitourinary toxicities in prostate cancer external beam radiotherapy: A scoping review. Diagnostics, 15.","DOI":"10.3390\/diagnostics15111331"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.3390\/curroncol30050383","article-title":"Dosimetric predictors of toxicity after prostate stereotactic body radiotherapy: A single-institutional experience of 145 patients","volume":"30","author":"Fujii","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5603\/RPOR.a2023.0043","article-title":"Acute toxicity and quality of life in prostate cancer patients treated with definitive hypofractionated pelvic radiation therapy: A single-center report","volume":"28","author":"Mandel","year":"2023","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Poon, D.M.C., Yuan, J., Yang, B., Wong, O.L., Chiu, S.T., Chiu, G., Cheung, K.Y., Yu, S.K., and Yung, R.W.H. (2022). A prospective study of stereotactic body radiotherapy (SBRT) with concomitant whole-pelvic radiotherapy (WPRT) for high-risk localized prostate cancer patients using 1.5 Tesla magnetic resonance guidance: The preliminary clinical outcome. Cancers, 14.","DOI":"10.3390\/cancers14143484"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hasterok, M., Szo\u0142tysik, M., Nowicka, Z., Goc, B., Gr\u00e4upner, D., Majewski, W., Ras\u0142awski, K., Rajwa, P., Jab\u0142o\u0144ska, I., and Magrowski, \u0141. (2023). Rectum and bladder toxicity in postoperative prostate bed irradiation: Dose-volume parameters analysis. Cancers, 15.","DOI":"10.3390\/cancers15225334"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","first-page":"100842","article-title":"Acute toxicity patterns and their management after moderate and ultra-hypofractionated radiotherapy for prostate cancer: A prospective cohort study","volume":"48","author":"Sinzabakira","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","article-title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: An individual patient data meta-analysis of six randomised trials","volume":"26","author":"Nikitas","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101766","DOI":"10.1016\/j.adro.2025.101766","article-title":"Association of circulating inflammatory biomarker levels and toxicity in patients undergoing pelvic radiation for cancer: A critical review","volume":"10","author":"Svensson","year":"2025","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1158\/1078-0432.CCR-08-2584","article-title":"Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer","volume":"15","author":"Bower","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: Version 2.0. An improved reference for grading the adverse effects of cancer treatment: Impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Stani\u0107, J., \u0160ovi\u0107, I., Jovanovic, L., Mati\u0107, I.Z., Niki\u0107, P., and Nikitovi\u0107, M. (2025). The role of predictive biomarkers in modern prostate cancer radiotherapy: A literature review on personalised treatment strategies and the prediction of adverse effects. Life, 15.","DOI":"10.3390\/life15071062"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/s41592-024-02305-7","article-title":"Large-scale foundation model on single-cell transcriptomics","volume":"21","author":"Hao","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06139-9","article-title":"Transfer learning enables predictions in network biology","volume":"618","author":"Theodoris","year":"2023","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s43856-026-01552-3","article-title":"Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity","volume":"6","author":"Assi","year":"2026","journal-title":"Commun. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:58:56Z","timestamp":1786697936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080479"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080479","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}